A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection

Annals of Surgical Oncology

Volumn 22, Issue 13, 2015, Pages 4217-4223

  Angioli, Roberto ^a   Capriglione, Stella ^a   Aloisi, Alessia ^a   Ricciardi, Roberto ^a   Scaletta, Giuseppe ^a   Lopez, Salvatore ^a   Miranda, Andrea ^a   Di Pinto, Anna ^a   Terranova, Corrado ^a   Plotti, Francesco ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; SECONDARY CYTOREDUCTIVE SURGERY; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; BLOOD; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEINS; RESEARCH DESIGN; ROC CURVE;

EID: 84947126332     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4534-z     Document Type: Article

References (21)

1. Ledermann JA, Raja FA. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer. 2011;47:S104–15.
2. Van de Laar, et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer. 2014;14:22.
3. Al Rawahi T, Lopes AD, Bristow RE. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;28:2.
4. Plotti F, Scaletta G, Aloisi A, Luvero D, Capriglione S, Miranda A, Montera R, De Cicco Nardone C, Terranova C, Angioli R. Quality of life in platinum-sensitive recurrent ovarian cancer: chemotherapy versus surgery plus chemotherapy. Ann Surg Oncol. 2015 Jan 13.
5. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J GynecolObstet. 2003;83:(1 Suppl):135–66.
6. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)DESKTOP OVAR Trial. Ann Surg Oncol. 2006;13(12):1702-10.
7. Harter P, Bois AD, Hahmann M, et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann SurgOncol. 2006;13:1702–10.
8. Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, et al. A risk model for second- ary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.
9. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117-23. doi:10.1007/s13277-012-0471-7. Epub 2012 Aug 9. PubMed PMID: 22875782.
10. Angioli R, Capriglione S, Aloisi A, Guzzo F, Luvero D, Miranda A, Damiani P, Montera R, Terranova C, Plotti F. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014;35(7):7009-15.
11. Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, Miranda A, Cafà EV, Damiani P, Benedetti-Panici P. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2012 Dec 7.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur JCancer. 2009;45(2):228-47.
13. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A, Luvero D, Cafà EV, Dugo N, Angelucci M, Benedetti-Panici P. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2012 Nov 20.
14. Angioli R, Miranda A, Aloisi A, Montera R, Capriglione S, De Cicco Nardone C, Terranova C, Plotti F. A critical review on HE4 performance in endometrial cancer: where are we now? Tumour Biol. 2013 Sep 26.
15. Angioli R, Capriglione S, Aloisi A, Luvero D, Cafà EV, Dugo N, Montera R, De Cicco Nardone C, Terranova C, Plotti F. REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy. Clin Cancer Res. 2013;19(20):5733-9.
16. Muzii L, Bellati F, Manci N, Zullo MA, Angioli R, Panici PB. Ringer’s lactate solution remains in the peritoneal cavity after laparoscopy longer than expected. Fertil Steril. 2005;84(1):148–53.
17. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–9.
18. Lee CK. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CAPLYPSO trial. Gynecol Oncol. 2015;136(1):18–24.
19. Chan JK, Sherman AE, et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol. 2011;29:832–8.
20. Plotti F, Capriglione S, Miranda A, Scaletta G, Aloisi A, Luvero D, Ricciardi R, Terranova C, De Cicco Nardone C, Angioli R. The impact of gynecologic oncology training in the management of cancer patients: is it really necessary? A prospective cohort study. Eur J ObstetGynecol Reprod Biol. 2015;184:19–23.
21. Fanfani F, Monterossi G, Fagotti A, Gallotta V, Costantini B, Vizzielli G, Petrillo M, Carbone MV, Scambia G. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer. Ann SurgOncol. 2014.